← Oncology Approval Tracker

FDA DECISION ·

Lazcluze + Rybrevant

lazertinib with amivantamab-vmjw · Janssen Biotech

FDA approvalNew therapyNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line use with amivantamab for adults with locally advanced or metastatic non-small cell lung cancer and an FDA test-confirmed EGFR exon 19 deletion or exon 21 L858R substitution.

LAMPGEN ANALYSIS

Why it matters

The lazertinib combination adds a first-line targeted regimen for common EGFR variants without a chemotherapy backbone.

What research teams should watch

Coordinate oral supply and infusion appointments, and check the label's venous thromboembolism prophylaxis instructions at initiation.

PRIMARY RECORDS

Sources